General Hospital of Northern Theater Command
Shenyang, Liaoning, 110016, China
Location status: Recruiting
NCT Number: NCT06216847
Coronary heart disease (CHD) stands as a foremost contributor to global mortality, characterized by complex pathogenesis that renders conventional "one-size-fits-all" preventive strategies inefficient. Therefore, the investigators designed a prospective, multi-center cohort study among patients hospitalized due to either confirmed or suspected CHD, which aimed to establish a holographic data set for the diagnosis and treatment of CHD and explore the impact of critical therapeutic strategies in the real world on the clinical outcomes of CHD patients, providing evidence to optimize the management pathway.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Shenyang, Liaoning, 110016, China
Location status: Recruiting
Coronary heart disease (CHD) stands as a foremost contributor to global mortality. Despite the increasing investment in the prevention of risk factors and the popularization of percutaneous coronary intervention (PCI), the age-standardized incidence and mortality of CHD continue to increase. CHD is characterized by complex pathogenesis, rendering conventional "one-size-fits-all" preventive strategies inefficient.
Currently, there is a need to address two critical challenges. The first centers on early detection, precise risk stratification, and personalized intervention strategies for high-risk CHD patients, with a focus on the exploration of inflammation-driven risks, lesion-based risk stratification, and tailored anti-thrombotic therapies. The second challenge lies in the transformation of clinical risk assessment and decision-making processes into a precise level through the utilization of big data mining techniques.
Therefore, the investigators designed a prospective, multi-center cohort study among patients hospitalized due to either confirmed or suspected CHD, which aimed to establish a holographic data set for the diagnosis and treatment of CHD and explore the impact of critical therapeutic strategies in the real world on the clinical outcomes of CHD patients, providing evidence to optimize the management pathway.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: During 12-month follow up
defined as the composite of cardiac death, myocardial infarction, or stroke
Time frame: During 1/2/3/4/5-year follow up
defined as a composite of all-cause death, myocardial infarction, ischemic stroke and target-vessel revascularization
Time frame: During 1/2/3/4/5-year follow up
Time frame: During 1/2/3/4/5-year follow up
Time frame: During 1/2/3/4/5-year follow up
defined as BARC types 3 or 5 bleeding events
Time frame: During 1/2/3/4/5-year follow up
defined as BARC type 2-5 bleeding events
Contact information is provided by the study sponsor or research team.
Shenyang Northern Hospital
Other
Clinical Outcomes of Patients With Coronary Artery Disease Cohort Study
Acronym: COCAD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07587099
Cardiovascular Diseases, Coronary Disease
Beijing, Beijing Municipality, China
View Trial DetailsNCT07244484
Anxiety Disorders, Cardiovascular Diseases
Shenyang, Liaoning, China
View Trial DetailsNCT07238920
Anxiety Disorders, Cardiovascular Diseases
Shenyang, Liaoning, China
View Trial DetailsNCT06170541
Cardiovascular Diseases, Coronary Disease
Baltimore, Maryland, United States
View Trial Details